ArticleApplied microbiology and biotechnology2026
Targeting thioredoxin reductase for anti-tuberculosis drug discovery: the inhibitor OSSL_632214.
Article in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The persistent prevalence of multidrug-resistant tuberculosis (TB) and extensively drug-resistant TB has progressively undermined the efficacy of TB infection control measures. Thus, developing innovative drugs that act on novel Mycobacterium tuberculosis (Mtb) targets is a strategic priority for global TB control efforts. This research direction offers a robust, evidence-based solution to the urgent, growing challenge of anti-TB drug resistance. Thioredoxin reductase (TrxB2, Rv3913) is an essential enzyme for the in vitro growth and survival of Mtb. At present, no anti-TB lead compounds targeting TrxB2 have been advanced for clinical translation, primarily due to challenges such as off-target drug side effects and insufficient target specificity. We employed a virtual screening approach to screen compounds from small-molecule libraries. We conducted further experiments, including enzyme activity assays and studies using overexpression strains, to verify the therapeutic target and mechanism of action of the hit compound. Using virtual screening, we discovered compound OSSL_632214, which exhibited potent anti-Mtb activity (MIC 3.13-6.25 μg/mL) in vitro and showed no cross-resistance with existing anti-TB drugs. In this study, we report for the first time the potent in vitro anti-Mtb activity of OSSL_632214, which possibly acts by targeting TrxB2 and inducing lipid peroxidation in Mtb. These findings provide a theoretical basis for developing novel anti-TB drugs targeting TrxB2. KEY POINTS: • Development of anti-TB drugs based on the novel target TrxB2 • OSSL_632214 exhibits anti-Mycobacterium tuberculosis activity • OSSL_632214 exhibits potential for the development of TrxB2-targeted drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.